Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be joining Ocugen as Senior Vice President, Commercial.

Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN) (Company), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that upon recommendation from the U.S. Food and Drug Administration (FDA), it will pursue submission of a biologics license application (BLA) for its COVID-19 vaccine candidate, COVAXIN™. The Company will no longer pursue an Emergency Use Authorization (EUA) for COVAXIN™.

Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate

The ability of this biotech to sell its coronavirus vaccine in a timely manner has caused a lot of headaches for investors.

Could Ocugen Be a Millionaire-Maker Stock?

The shares of Ocugen Inc (NASDAQ: OCGN) have received a price target of $10 by Roth Capital. These are the details.

OCGN Stock Price: $10 Target By Roth Capital

The biopharmaceutical company, known for its portfolio of eye therapy drugs, has a COVID-19 vaccine in the works.

Why Ocugen Stock Fell 31.1% in May

Today, OCGN stock is on the move as the company announced its intention to expand its commercialization rights to include Canada. The post OCGN stock: The Big COVAXIN News Boosting Ocugen Today appeared first on InvestorPlace.

OCGN stock: The Big COVAXIN News Boosting Ocugen Today

Atossa Genetics

Bionano Genomics

GT Biopharma Inc

AMC stock ignites momentum in small cap penny stocks this month. The post Hot Penny Stocks To Watch As AMC Stock Ignites Small Caps In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Watch As AMC Stock Ignites Small Caps In June

The company will be submitting for emergency use of Covaxin. The FDA Advisory Committee and the agency itself will be deciding the vaccine's fate, which will likely be favorable.

Buy Ocugen For Imminent Catalysts

After sprinting to $16.20 in early May, Ocugen's fallen back to earth. What does it have to do to get OCGN stock back into double digits?

When It Comes to Ocugen Stock I'm Damned If I Do or Don't

This New Vaccine Market Could Be Bigger for Ocugen Than the U.S.

Sanofi

Valneva SE

Arcturus Therapeutics

CureVac B.V

Novavax

Dr. Reddy's Labs

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on InvestorPlace.

7 Best Vaccine Stocks for Their Pipeline Potential

OCGN stock is attempting an upward move on unrealistic expectations. There is no reason to believe it can move upward long term.

The Same Problems Persist for Ocugen in Marketing Covaxin

MALVERN, Pa. and HYDERABAD, India, June 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, and Bharat Biotech, a global leader in vaccine innovation, today announced that they have entered into an amendment to their Co-development, Supply, and Commercialization Agreement to expand Ocugen's exclusive territory to commercialize COVAXIN™ to now also include Canada, in addition to Ocugen's existing rights to commercialize COVAXIN™ in the United States.

Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada

The agency's revised emergency-authorization guidance for COVID-19 vaccines appears to present a significant hurdle for Ocugen.

Did the FDA Slam the Door on Ocugen's Chances of Winning Authorization for Covaxin?

The FDA's recent warning that it could reject some applications for EUAs from vaccine makers does not portend well for Ocugen's aspirations. OCGN stock remains an excellent name to sell short.

FDA's Vaccine Attitude, New Data Don't Bode Well for Ocugen Stock

An EUA for its coronavirus vaccine candidate may be on the horizon.

How Risky Is Ocugen?

OCGN stock is a speculative bet. FDA approval of Covaxin would boost the shares.

Ocugen Stock Is a Speculative Covid-19 Vaccine Bet

Ocugen Inc (NASDAQ: OCGN) shares gained 13.71% to $8.71 Thursday after the company announced it's on track to submit its Emergency Use Authorization application to the FDA for its COVID-19 vaccine candidate COVAXIN. Ocugen is a clinical-stage biopharmaceutical company.

Why Ocugen Stock Is Moving Today

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by over 10% during intraday trading today. This is why it happened.

OCGN Stock Price: Over 10% Increase Explanation

Ocugen will only make money from sales of its vaccine in the United States, but by the time that's possible, it'll be too late. The post Ocugen Stock Will Probably Drop Below $1 appeared first on InvestorPlace.

Ocugen Stock Will Probably Drop Below $1

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Ocugen (OCGN) Stock?

While OCGN stock produced one of the most remarkable rides in the market, it's time to get off this train before it derails. The post Take Your Ocugen Stock Profits and Run If You Haven't Already appeared first on InvestorPlace.

Take Your Ocugen Stock Profits and Run If You Haven't Already

Ocugen has swung to new highs and lows this year on news around its partnership for Covaxin. Today's announcement could stoke further progress speculation.

OCGN Stock: The Big FDA News Lifting Ocugen Shares Today

The company has a path to success in the COVID-19 vaccine market, but it might be more of an uphill climb than some investors realize.

2 Reasons to Avoid Ocugen Stock -- and 1 Reason to Considering Buying It

Shares of Ocugen Inc. (NASDAQ: OCGN), India-based Bharat Biotech's U.S. partner for COVID-19 vaccine Covaxin, fell 3.7% in Wednesday's regular trading session. What Happened: Ocugen said late Wednesday it plans to submit an Emergency Use Authorization (EUA) application for Covaxin to the U.S. Food & Drug Administration (FDA) in June.

News for Ocugen, Inc. Stock (OCGN)